Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 15 (5) (k)-(l): Difference between revisions
From GxPlex
Migrate to Template:ReferenceData for PageForms (GxPlexBot) |
Gxplex admin (talk | contribs) m 1 revision imported |
(No difference)
| |
Latest revision as of 13:49, 16 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 2 — Unit 2.3.4 |
| Scope | HM |
| Document part | Article 15
(5) (k)-(l) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Ethics committee, Participant compensation, Written agreement, Safety |
Content
Ethics committee opinion 15.— [...] (5) In preparing its opinion, the committee shall consider, in particular, the following matters— (k)the amounts, and, where appropriate, the arrangements, for rewarding or compensating investigators and subjects; (l)the terms of any agreement between the sponsor and the owner or occupier of the trial site which are relevant to the arrangements referred to in sub-paragraph (k)
